Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer. Mr. Ahlers will report to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.

Mr. Ahlers joins Cue at a pivotal point in the Company's evolution with a recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy and anticipated Phase 2 CSU data readout for the program by the end of the quarter. As Cue continues to rapidly mature as a clinical-stage biotech company, Mr. Ahlers will help strengthen the Company's financial leadership and infrastructure and support execution of its corporate strategy.